

Case Report

Open Access

Very Rare Case Report of Multiple Sclerosis in a Case of Chronic Kidney Disease

Vajed Mogal^{*1} and Mahendra Wawhal²

¹Assistant Professor (DM Nephrology) – Consultant Nephrologist, Department of Nephrology, M.G.M. Medical College & Hospital, Aurangabad, Maharashtra, India

²Associate Professor– Senior Consultants (MD Medicine), Department of Medicine, M.G.M. Medical College & Hospital, Aurangabad, Maharashtra, India

ABSTRACT

Multiple sclerosis is a neurological disease, which affects young adults. Its course is unpredictable and runs over decades. It is considered as disease of unknown etiology in which there is demyelination of the brain and spinal cord.

There is one case report of membranous GN in a case of progressive multiple sclerosis in the extant world literature. We report here perhaps the first case in the world of the occurrence of multiple sclerosis in a known case of chronic kidney disease with the presentation of acute optic neuritis, having a characteristics picture on MRI of multiple sclerosis in brain, abnormal VEP, oligoclonal bands in CSF and a prior episode of acute optic neuritis 3 years back. In our opinion, this case opens the flood gates for research & work to investigate whether the oxidative stress and the smouldering proinflammatory state in CKD can precipitate multiple sclerosis in a genetically predisposed host in a given environment. Multiple Sclerosis is often associated with a neurogenic bladder, but renal function is generally considered to be normal [1].

*Corresponding author

Dr. Vajed Mogal, Assistant Professor (DM Nephrology) – Consultant Nephrologist, Department of Nephrology, M.G.M. Medical College & Hospital, Aurangabad, Maharashtra, India. E-mail: drvajedmogal@gmail.com

Received: August 11, 2020; **Accepted:** August 23, 2020; **Published:** September 28, 2020

Keywords: Multiple Sclerosis (MS), Chronic Kidney Disease (CKD), methylprednisolone.

Introduction

Multiple sclerosis (MS) is a rare demyelinating disorder of the central nervous system [2]. It is a complex human autoimmune-type disease with predominantly unknown etiology [3]. The prevalence of MS disease ranges from 30 to 100 cases per 100000 individuals [4]. MS, like other presumed autoimmune diseases, is more common in females and often first manifests clinical symptoms during young adulthood [5]. MS affects young adults; its course is unpredictable and runs over decades. The demyelination seen in MS provides a permitting condition for axonal degeneration, which seems to be causative of permanent neurologic deficit [6].

The prevalence of renal disease (unspecified) in multiple sclerosis ranged from 0% to 0.78% [7]. However the occurrence of multiple sclerosis in CKD has not been reported in literature except for one case of membranous glomerulonephritis in a case of progressive multiple sclerosis. Here, we report a very rare and first case of multiple sclerosis in a case of chronic kidney disease.

Case report


A 58-year-old male, known case of hypertension since 5 years & on regular treatment, admitted with complaints of sudden painless loss of vision since 3 days in left eye with blind right eye since

3 years. Patient had history of right eye acute optic neuritis with total loss of vision 3 years back. He had no addiction of tobacco or alcohol. The past medical history was insignificant.

3 years back, he had acute optic neuritis of right eye with sudden painless complete loss of vision. He went to the hospital on the 5th day where he was investigated & found to have normal MRI and normal fundus examination but his kidney function tests were deranged (S. creatinine 3.5, Urea 90). There was no signs of uremia & both kidneys show bilateral shrunken kidneys on ultrasound (USG) & output was adequate. He was treated but his vision did not recovered. There was no history of NSAIDs or any other drug abuse. No signs of uremia were present. Patient had no immediate complain except loss of vision.

On examination, he was conscious, oriented, afebrile with pulse of 100/min, blood pressure of 200/110 mm of Hg, respiratory rate was 18/min & SpO2 was 98 % on room air. Systemic examination was unremarkable. He was euvoletic without pericardial rub. Routine labs were sent. Electrocardiogram (ECG) showed sinus tachycardia and x-ray chest was normal. Laboratory investigations revealed haemoglobin of 7.8 gm%, WBC of 10,000/mm³, platelet count of 180,000/mm³. Serum electrolytes and liver function were normal. Kidney functions were deranged with urea of 140 & serum creatinine was 7.5mg/dl but with adequate urine output. Serum calcium was low and serum phosphorus was normal. His ANCA profile as well as Sr. ANA, dsDNA were negative. Iron

studies showed chronic iron deficiency. Ultrasound of abdomen showed bilateral shrunken kidneys with loss of CMD suggestive of chronic kidney disease. Fundus examination was normal except for hypertensive retinopathy and optic atrophy in right eye.



MRI Brain (Figure 1): cerebral white matter lesion suggestive of MS.

We suspected of optic neuritis and did MRI Brain (figure 1) which showed white matter hypodensity in periventricular area, temporo-parietal cortices and cerebellum suggestive of multiple sclerosis. His VEP (Visual Evoked Potentials) were abnormal.

His CSF was sent which showed acellular & CSF electrophoresis showed oligoclonal bands. Hence, we started him on I.V. methyl-prednisolone 1 gm for 3 days which improved his vision to almost complete recovery with normal vision in the right eye.

He was under regular follow up and did not complain any visual problems. Here, we report case of optic neuritis due to multiple sclerosis in a case of chronic kidney disease.

Discussion

Multiple Sclerosis, a chronic inflammatory and neurodegenerative disease of the central nervous system, characterized by recurrent relapses of central nervous system inflammation ranging from mild to severely disabling. Multiple sclerosis, also known as disseminated sclerosis or encephalomyelitis disseminates. The insulating covers of nerve cells in the brain and spinal cord damaged in an inflammatory disease. This damage disrupts the ability of parts of the nervous system to communicate and resulting in a wide range of signs and symptoms [8,9].

It was first described by Jean-Martin Charcot, a French researcher, in 1868, and affects more women than men [10,11]. Its incidence is found to be 5.68/100,000 per year [12]. MS is believed to be an autoimmune disorder that damages central nervous system (CNS) myelin and axons. Typically, MS begins as a relapsing-remitting disease and evolves over time to a chronic secondary progressive condition that can lead to severe disability and even death [13].

In the mid-1990s, the modern therapeutic era began for multiple sclerosis (MS). While the initial disease modifying therapies had some adverse effects, such as hepatotoxicity, they have been relatively well tolerated and issues related to co-morbidity either increasing the risks of recognized adverse effects or being themselves adverse effects – have not been a significant concern [14]. The prevalence of renal failure in multiple sclerosis ranged from 0% to 0.78%, with the highest estimate being from one population-based Taiwanese study [15]. Chronic kidney failure has become a global epidemic [16].

The etiology of the decreased in GFR is likely multifactorial and may represent the combined effects of chronic neurogenic bladder (incomplete emptying, frequent urinary tract infections and pyelonephritis, and nephrolithiasis), as well as increased exposure

to other nephrotoxic drugs (nonsteroidal anti-inflammatory drugs [NSAID], antibiotics, and certain contrast dyes), and the marked tendency for disabled patients to remain chronically dehydrated to avoid frequent micturition. MS derived its term from the multiple scarred areas in the brain termed plaques. The acute lesion in MS is characterized by perivenular cuffing and tissue infiltration by mononuclear cells predominantly T lymphocytes and macrophages. As the lesion evolves, demyelination occurs, with macrophages and microglial cells scavenging the myelin debris. Proliferation of astrocytes lead to scar formation.

Lesions of MS typically occur at different times and in different CNS locations (i.e., disseminated in time and space). Multiple sclerosis takes several forms, with new symptoms in either isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; or permanent neurological problems often occur, especially as the disease advances [17]. The most common initial symptoms include weakness in one or more limbs, blurring of vision secondary to optic neuritis, sensory disturbances, diplopia and ataxia [18]. Disability and severity is measured by the expanded disability status scale (EDSS) [19].

As the disease progresses and disability increases, it can become difficult to differentiate the symptoms and signs of MS from those of other potentially emerging neuro-degenerative conditions. The literature contains many reports of the concurrence of MS and other neurologic conditions [20]. Moreover, although MS is an upper motor neuron (UMN) disease, lower motor neuron (LMN) findings—including muscle atrophy, especially in hand muscles—have been reported [21]. Theoretically, MS-related muscle atrophy could be due to disuse, associated peripheral neuropathy, involvement of brainstem or spinal gray matter structures, or involvement of the ventral roots at their exit zone. It has an insidious onset and course, without a major contribution to the patient's complaints and dysfunction. Therefore, it is wise to be suspicious about this finding, especially when it is a source of dysfunction or is associated with a significant change in disease progression [22,23].

Renal side effects are uncommon. There exists one case report describing a case of membranous glomerulonephritis and thrombocytopenia in a patient with progressive multiple sclerosis [24]. Swanton and colleagues, in 2007, and Montalban and colleagues, in 2010, have made important contribution on the diagnosis of MS proposing simpler criteria allowing easier MRI evidence for dissemination in space (DIS) and dissemination in time (DIT) to be used in patients who present with clinically isolated syndrome (CIS), respectively [25,26]. CSF abnormalities consist of mononuclear cell pleocytosis, an elevation in the level of total Ig, and the presence of oligoclonal Ig. Evoked response testing may detect slowed or abnormal conduction in visual, auditory, somatosensory, or motor pathways. On MRI, periventricular lesions may be found on T2 weighted MRI brain scans. However, no clinical sign or diagnostic test finding is unique for MS.

The use of MRI has had a major impact on allowing the early and more precise diagnosis of the disease [27]. Management of MS may be divided into two categories consisting of; a) treatment designed to arrest the disease process and b) symptomatic therapy. Immunosuppressive drugs remain the cornerstone of therapy in the first modality of treatment, although their efficacy is limited and their chronic use entails considerable risk [28]. Mild acute exacerbations that do not produce functional decline may not require treatment. When functional ability is affected, the standard

intervention is intravenous injection of high-dose corticosteroids [29].

Intravenous methyl-prednisolone has been shown to shorten the duration of acute exacerbations [30]. The mechanism of action of corticosteroids used for acute relapses is not completely clear, but may involve the following actions: Prevention of inflammatory cytokine activation, Inhibition of T-cell activation, prevention of immune cells from entering the CNS and Increased death of activated immune cells. Corticosteroids hasten functional recovery after relapses [31,32]. Therefore, it is important to establish the diagnosis and management in patients with ocular damage which leads to multiple sclerosis.

Conclusion

We report here a very rare and perhaps first case of multiple sclerosis in literature so far that presented with acute optic neuritis in left eye that rapidly improved with IV Methylprednisolone for 3 days. The patient had a characteristic picture of white matter lesions in the cerebral cortex, cerebellum, periventricular lesion and optic atrophy in right eye, with oligoclonal bands in CSF, and abnormal VEP in a diagnosed case of chronic kidney disease with bilateral shrunken kidneys and severely deranged renal functions.

The occurrence of multiple sclerosis in the setting of chronic kidney disease has not been mentioned anywhere in literature. There has been a single case report of membranous glomerulonephritis with thrombocytopenia in a case of progressive multiple sclerosis.

The occurrence of acute renal injury due to neurogenic bladder subsequent to stasis of urine and infections as well as to dehydration in a bedridden patient of multiple sclerosis is understood. Also, the affection of kidneys due to other associated or complicating infections or drug insult and subsequent renal injury or renal failure in a case of multiple sclerosis is also not known.

However, here we report a case of established CKD and the occurrence of multiple sclerosis later which may perhaps be the first case report in literature in India and world.

This case, in our opinion opens the flood gates for research and investigation as to whether the oxidative stress and proinflammatory states in CKD serves to precipitate the dreaded condition of multiple sclerosis in a genetically predisposed host in a given environment.

References

1. Rashid TM, Hollander JB (1998) Multiple sclerosis and the neurogenic bladder. *Phys Med Rehabil Clin N Am* 9: 615-629.
2. Seamons A, Perchellet A, Gorman J (2003) Immune tolerance to myelin proteins. *Immunol Res* 28: 201-222.
3. Lutton JD, Winston R, Rodman TC (2004) Multiple sclerosis: aetiological mechanisms and future direction. *Exp Biol Med* 229: 12-20.
4. Zawada M, Liwien II, Pernak M, Januszkiewicz-Lewandowska D, Nowicka-Kujawska K et al. (2003) MSRV pol sequence copy number as a potential marker of multiple sclerosis. *Pol J Pharmacol* 55: 869-875.
5. Halfer DA (2004) Multiple sclerosis. *J Clin Invest* 2113: 788-794.
6. Althaus HH (2004) Remyelination in multiple sclerosis: a role for neutrophins? *Prog Brain Res* 146: 415-432.
7. Horton M, Rudick RA, Hara-Cleaver C, Marrie R.A (2010) Validation of a Self-report comorbidity questionnaire for multiple sclerosis. *Neuroepidemiology* 35: 83-90.
8. Compston A, Coles A (2008) "Multiple sclerosis". *Lancet* 372: 17-1502.
9. Compston A, Coles A (2002) "Multiple sclerosis". *Lancet* 359: 31-1221.
10. M. Clanet (2008) "Jean-Martin Charcot. 1825 to 1893," *International MS Journal/MS Forum* 15: 59-61.
11. C. Jobin, C Larochelle, H Parpal, P K Coyle, P Duquette (2010) "Gender issues in multiple sclerosis: an update," *Women's Health* 6: 797-820.
12. J. Benito-Le (2011) on, "Are the prevalence and incidence of multiple sclerosis changing?" *Neuroepidemiology* 36: 148-149.
13. Ebers GC (2000) The natural history of multiple sclerosis. *Neurol Sci* 21: S815-S817.
14. Tremlett HL, Yoshida EM and Oger J (2004) Liver injury associated with the {beta}-interferons for MS: A comparison between the three products. *Neurology* 62: 628-631.
15. Kang J-H, Chen Y-H and Lin H-C (2010) Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. *Eur J Neurol* 17: 1215-1219.
16. Coresh J, Selvin E, Stevens LA, et al. (2007) Prevalence of chronic kidney disease in the United States. *JAMA* 298: 2038-2047.
17. Lublin FD, Reingold SC, Cohen JA, et al. (2014) "Defining the clinical course of multiple sclerosis". *Neurology* 83: 86-278.
18. Alastair Compston, Christian Confavreux, Hans Lassmann (2006) *McAlpine's Multiple Sclerosis*, 4th edition, Elsevier Inc 6: 287-346.
19. Rudick RA, Cutter G, Reingold S (2002) "The multiple sclerosis functional composite: a new clinical outcome measure for multiple sclerosis trials". *Mult. Scler* 8: 65-359.
20. Finke C, Siebert E, Plotkin M, Wenning GK, Reuter U (2010) Multiple system atrophy masking multiple sclerosis. *Clin Neurol Neurosurg* 112: 59-61.
21. Fisher M, Long R, Drachman D (1983) Hand muscle atrophy in multiple sclerosis. *Arch Neurol* 409: 811-815.
22. Shefner J, Mackin G, Dawson D (1992) Lower motor neuron dysfunction in patients with multiple sclerosis. *Muscle Nerve* 15: 1265-1270.
23. Magee CC (2001) Renal thrombotic microangiopathy induced by interferonalpha. *Nephrol Dial Transplant* 16: 2111-2112.
24. Emsley HC, Molloy J (2002) Inflammatory demyelinating polyradiculoneuropathy associated with membranous glomerulonephritis and thrombocytopenia. *Clin Neurol Neurosurg* 105: 23-26.
25. J K Swanton, A Rovira, M Tintore et al., (2007) "MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study," *The Lancet Neurology* 6: 677-686.
26. X. Montalban, M. Tintore, J. Swanton et al., (2010) "MRI criteria for MS in patients with clinically isolated syndromes," *Neurology* 74: 427-434.
27. McDonald WI (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international Panel on the diagnosis of multiple sclerosis. *Ann Neurol* 50: 121-127.
28. Michalowska-Wender G, Losy J, Wender M, Januszkiewicz-Lewandowska D, Nowak J (2003) Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers. *Pol J Pharmacol* 55: 877-880.
29. Kaufman DI, Trobe JD, Eggenberger ER, J.N. Whitaker (2000) Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. *Neurology* 54: 2039-2044.
30. Zivadinov R, Rudick RA, De Masi R, D. Nasuelli, M. Ukmar et al. (2001) Effects of IV methylprednisolone on

-
- brain atrophy in relapsing-remitting MS. Neurology 57: 1239-1247.
31. Anderson PB, Goodkin DE (1998) Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci 160: 16-25.
32. Fleming, JO (2013) "Helminth therapy and multiple sclerosis". International Journal for Parasitology 43: 259-274.